CytRx Corporation RNAi Subsidiary, RXi Pharmaceuticals, Announces Worldwide Research and Therapeutic RNAi Licensing Agreement with Cold Spring Harbor Laboratory
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR) today announced that its majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), has secured a non-exclusive, worldwide research and therapeutic license from Cold Spring Harbor Laboratory to their short hairpin RNAi technology (shRNAi). The licensed technology potentially allows for the more efficient triggering of RNA interference (RNAi) and includes the use of short hairpin RNAis (shRNAis) either delivered as RNA compositions or encoded by DNA constructs. Patents covering this technology are currently pending. Financial terms were not disclosed for competitive reasons.